① Seven listed companies with difficult annual reports were filed by the Securities Regulatory Commission on the same day; ② the problems of Dongxu Optoelectronics and Dongxu Blue Sky are unclear; ③ the problems of Weichuang Co., Ltd. and Puli Pharmaceuticals are relatively clear; ④ the risks of the remaining 3 companies that wear hats have long been perceived by the market.
Financial Services Association, May 9 (Reporter Luo Yichen) The disclosure period for 2023 annual reports has passed, and listed companies that have not handed over their “report cards” on schedule are also facing regulatory processing. On the evening of May 8, seven listed companies announced that they had received a “Notice of Case Filing” issued by the Securities Regulatory Commission due to difficult production of annual reports, adding another impetus to the strong regulatory trend of A-shares.
On the evening of the 8th, Weichuang Co., Ltd. (002308.SZ), Dongxu Optoelectronics (000413.SZ), Dongxu Blue Sky (000040.SZ), Puli Pharmaceuticals (300630.SZ), *ST Sansheng (300282.SZ), *ST Yuebo (300742.SZ), and ST Huatie (000976 .SZ) issued an announcement that a case was filed by the Securities Regulatory Commission for not disclosing the 2023 annual report within the specified period. Long before the announcement of the filing of the case, trading of the shares of 7 companies had already been suspended one after another in accordance with regulations.
Also, annual reports are difficult to produce; the actual situation of the 7 companies is different. Among them, the two “Dongxu” companies, Dongxu Optoelectronics and Dongxu Blue Sky, both suddenly exploded, which caught investors by surprise.
Also a listed company under Dongxu Group Co., Ltd., Dongxu Optoelectronics and Dongxu Blue Sky both chose delaying tactics in the face of “annual reports that are difficult to produce.” In the absence of warning, the two companies chose to issue a change announcement on the day of disclosure of their annual reports on April 27, slightly delaying the publication period by three days. After waiting until April 30, the annual report was announced and could not be disclosed on time, and the stock trading was automatically suspended.
Compared to the “Dongxu series” concealment and delay, it is clear that Weichuang Co., Ltd. and Puli Pharmaceuticals “annual reports are difficult to produce”.
This round of Weichuang's crisis was first triggered by the equity transfer crisis last year. As a result, Liu Jun, the actual controller of Fangxiling Energy, and Lu Keping, the company's upper shareholder, were successively filed by the Securities Regulatory Commission. The core issue, Liu Jun's illegal occupation of 1.33 billion yuan of Weichuang's capital, has been slow to resolve, which ultimately caused the listed company's 2023 annual report to be difficult to produce.
Puli Pharmaceuticals, on the other hand, is deeply troubled by the financial data for previous years. Since financial data for 2021 and 2022 could not be determined, it became difficult to determine the company's initial financial period in 2023, so the annual report also declared production difficult.
The remaining three companies that wear hats have long been fraught with problems. They continue to receive various letters of concern and warning letters. The related risks have long been perceived by the market. This “annual report is difficult to produce” is not a surprise.